<DOC>
	<DOCNO>NCT02624830</DOCNO>
	<brief_summary>The purpose study investigate long term response sulfonylurea glucose control child diabetes due mutation ABCC8 switch insulin injection sulfonylurea tablet .</brief_summary>
	<brief_title>Long-Term Sulfonylurea Response ABCC8 Neonatal Diabetes ( SuResponsSUR )</brief_title>
	<detailed_description>Neonatal diabetes mellitus rare , monogenic form diabetes occur first 6-9 month life characterize hyperglycemia require exogenous insulin therapy . The estimated incidence 1 per 12000 newborn . Although homozygous compound heterozygous mutation gene IPF1 ( Stoffers et al. , 1997 ) GCK ( Nj√∏lstad et al. , 2001 ) first genetic cause disease identify , activate mutation KIR6.2 sulfonylurea receptor 1 ( SUR1 ) subunits pancreatic ATP-sensitive K+ channel , cod gene KCNJ11 ABCC8 , recently identify major cause transient permanent neonatal diabetes ( Gloyn et al. , 2004 ; Babenko et al. , 2006 ) . In normal pancreatic beta-cell , metabolism result increase cellular ATP , bind KIR6.2 . The potassium channel subsequently close hence depolarizes membrane initiate insulin release via increased calcium entry . Conversely , increase cellular ADP act SUR1 open channel prevent insulin release . Activating mutation channel reduces sensitivity inhibitory action ATP increase sensitivity stimulatory action ADP . This cause ATP-sensitive K+ channel remain open , even presence glucose , therefore prevent insulin release . Sulfonylureas act ATP-independent mechanism close channel even mutation present . Sulfonylureas result insulin release therefore immediately consider show potential treatment option neonatal diabetes cause mutation channel ( Sagen et al. , 2004 ) . The effective replacement insulin treatment high-dose sulfonylurea show successful 90 % patient Kir6.2 mutation ( Pearson et al. , 2006 ) 85 % patient SUR1 mutation ( Rafiq et al. , 2008 ) result improved glycemic control . This dramatic effect sulfonylurea standard , world-wide treatment neonatal diabetes due mutation either KCNJ11 ABCC8 . There , however , far information long-term use sulfonylurea patient KCNJ11 ABCC8 mutation . The investigator therefore initiate international , multicenter , prospective study aim include 75 patient age 9 year genetic diagnosis diabetes due ABCC8 gene mutation identify sequence Bergen , Norway ; Exeter , U.K. ; Paris , France Rome , Italy . Most patient refer base membership International Society Pediatric Adolescent Diabetes . All patient attempt transfer treatment insulin sufficient dose sulfonylurea . No selection criterion apply , patient include outcome data follow attempted transfer . The observation period least 9 year commence sulfonylureas patient . The study conduct accordance Declaration Helsinki inform consent obtain participate patient , parental consent give behalf child .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Infant , Newborn , Diseases</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Permanent diabetes due mutation ABCC8 ( SUR1 ) Patients successfully transfer insulin sulfonylurea Transferred sulfonylurea treatment November 1 , 2006 ( ie 9 year insulin ) Willing able provide inform consent ( parent younger 16 year age ) Permanent diabetes due mutation ABCC8 ( SUR1 ) Patients successfully transfer insulin sulfonylurea Transferred sulfonylurea treatment November 1 , 2006 ( ie les 9 year insulin ) Not willing able provide inform consent ( parent younger 16 year age )</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>